InspireMD reported third‑quarter 2025 financial results, posting total revenue of $2.52 million, up 39% from $1.80 million in the same period last year. The company recorded a net loss of $12.71 million, compared with a $7.90 million loss in Q3 2024. Earnings per share were $‑0.17, beating the consensus estimate of $‑0.19.
U.S. revenue for the quarter was $497,000, while international revenue was $2.02 million. The U.S. launch of the CGuard Prime carotid stent system on July 9 2025 generated measurable revenue in its first quarter, with more than 100 procedures performed in leading hospitals.
Gross profit rose to $864,000 from $414,000, driven by a higher margin mix. Operating expenses increased to $13.90 million, a 57% rise from $8.90 million in Q3 2024, largely due to expanded U.S. commercialization and headcount costs. Cash and cash equivalents stood at $63.40 million, up from $34.60 million at the end of 2024, and the company added $58.00 million in gross proceeds in July.
Revenue estimates for the quarter were in the range of $1.80 million to $1.92 million, so the reported $2.52 million beat expectations. The company did not provide a sequential comparison for Q2 2025 or forward guidance for the next quarter or fiscal year.
Management highlighted the successful U.S. launch as a key driver of growth and emphasized continued investment in U.S. commercialization, while noting that operating expenses remain high as the company expands its commercial footprint.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.